<SEC-DOCUMENT>0001144204-18-048734.txt : 20180910
<SEC-HEADER>0001144204-18-048734.hdr.sgml : 20180910
<ACCEPTANCE-DATETIME>20180910091401
ACCESSION NUMBER:		0001144204-18-048734
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180906
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180910
DATE AS OF CHANGE:		20180910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13341
		FILM NUMBER:		181061558

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv502612_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C.&nbsp; 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):
September 6, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Titan
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-13341</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3171940</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number) </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(IRS Employer Identification No.) </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>400 Oyster Point Blvd., Suite 505, South
San Francisco, CA</B> 94080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>650-244-4990</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's telephone number including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's former name or former address,
if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Soliciting material pursuant to Rule 14a-12(b) under the
Exchange Act (17 CFR 240.14a-12(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01.</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 6, 2018, Titan Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
was awarded a grant by the National Institutes of Health (&ldquo;NIH&rdquo;) National Institute of Drug Abuse (&ldquo;NIDA&rdquo;)
in support of development of a six-month implantable formulation of Nalmefene, an opioid antagonist, for the prevention of relapse
to opioid addiction, following opioid detoxification. The grant provides for $2,666,592 in funding during the first year and $4,050,000
during the second year subject to the terms and conditions specified in the grant, including a fund matching obligation of the
Company in the amount of $1,333,295 during the first year and $2,025,000 during the second year. Funding during the second year
is also subject to satisfactory progress of the project and the availability of funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release issued by the Company is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 16, 2018, Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH)
announced that Scott Smith, a member of our board of directors, had been appointed to its board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial
                                         Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">Exhibit No.</TD><TD STYLE="text-align: justify">Description</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><A HREF="tv502612_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv502612_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release, dated September 10, 2018.</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&nbsp;&#8232;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">TITAN PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>/s/ Sunil Bhonsle&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;Sunil Bhonsle</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer and President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: September 10, 2018</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 283.5pt; text-indent: -283.5pt">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv502612_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TITAN AWARDED NIDA GRANT FOR THE DEVELOPMENT
OF A NALMEFENE IMPLANT FOR THE PREVENTION OF OPIOID ADDICTION RELAPSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SOUTH SAN FRANCISCO, CA &ndash; September
10, 2018 &ndash; Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that it has been awarded a two year grant of approximately
$6.7 million from the National Institutes of Health&rsquo;s National Institute on Drug Abuse (NIDA) for the development of a ProNeura&trade;
based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction,
following opioid detoxification. The grant provides approximately $2.7 million for the project from now through August 31, 2019,
with the balance to be funded over the subsequent year, subject to satisfactory project progress, fund availability and certain
other conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;NIDA previously provided funds for
an important Phase 3 trial of our approved product, Probuphine<SUP>&reg;</SUP>, and we are grateful for this additional vote of
confidence in our ProNeura technology as well as our ability to execute on another program for the treatment of opioid addiction,&rdquo;
said Titan&rsquo;s Chief Scientific Officer and Principal Investigator of the project, Dr. Kate DeVarney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Titan was awarded this grant following
an in-depth evaluation by NIDA of the Company&rsquo;s proposed research for scientific and technical merit. The grant provides
approximately half of the expenses associated with the completion of non-clinical studies which, if successful, are expected to
support the Company&rsquo;s submission of a Nalmefene six-month implant Investigational New Drug Application to the U.S. Food and
Drug Administration (FDA). Titan retains full commercial rights to the Nalmefene implant product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This NIDA grant serves as further
validation of the importance of long-term treatment options in addiction medicine,&rdquo; said Titan's President and CEO, Sunil
Bhonsle. &ldquo;As we continue to make progress in transitioning to a commercial company marketing Probuphine, we believe that
our Nalmefene implant has the potential to become an important addition to our product portfolio for addressing opioid addiction,
a global health emergency.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Titan Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Titan Pharmaceuticals, Inc. (NASDAQ:TTNP),
based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura&trade; long-term,
continuous drug delivery technology. The company's lead product is Probuphine<SUP>&reg;</SUP>, a novel and long-acting formulation
of buprenorphine for the long-term maintenance treatment of opioid dependence. Approved by the FDA in May 2016, Probuphine is the
first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine
for six months following a single procedure. The ProNeura technology also has the potential to be used in developing products for
treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock
blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit
www.titanpharm.com.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release may contain &quot;forward-looking
statements&quot; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other
statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's
current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval
process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and
strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based, except as required by law. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CONTACTS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunil Bhonsle,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President &amp; CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(650) 244-4990</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephen Kilmer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(650) 989-2215</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">skilmer@titanpharm.com</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 -\# 2(  A$! Q$!_\0
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M._\ '_\ XJC_ (7!K7_/AI__ (__ /%4>TB']AXSLOO1[-17C7_"W];Z#3[
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M (#H*VZ**:5B:E252;G-W;"BBB@@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
